Tarlatamab (AMG 757) Expanded Access Protocol for Advanced Small Cell Lung Cancer
NCT06064500
·
clinicaltrials.gov ↗
APPROVED_FOR_MARKETING
Status
INDUSTRY
Sponsor class
Conditions
Small Cell Lung Cancer
Interventions
DRUG:
Tarlatamab
Sponsor
Amgen